-
1Academic Journal
Συγγραφείς: V. A. Parfyonov
Πηγή: Медицинский совет, Vol 0, Iss 5, Pp 28-33 (2015)
Θεματικοί όροι: болезнь альцгеймера, ингибиторы центральной ацетилхолинэстеразы, донепезил, галантамин, ривастигмин, мемантин, alzheimer's disease, central acetylcholinesterase inhibitors, donepezil, galantamine, rivastigmine, memantine, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/169; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/b100b953bbe94172ac5ed528ee71c3fd
-
2Academic Journal
Συγγραφείς: A. A. Naumenko, I. S. Preobrazhenskaya
Πηγή: Медицинский совет, Vol 0, Iss 5, Pp 46-54 (2015)
Θεματικοί όροι: болезнь альцгеймера, церебральный амилоидоз, базисное симптоматическое лечение, ингибиторы центральной ацетилхолинэстеразы, блокаторы nmda-рецепторов, акатинола мемантин, гантенерумаб, церебролизин, alzheimer's disease, cerebral amyloidosis, basic symptomatic treatment, central acetylcholinesterase inhibitors, nmda-receptor blockers, akatinol, memantine, gantenerumab, cerebrolysin, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/172; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/0ef9923e3e2e4000ba1cd4e9cf13789b
-
3Academic Journal
Συγγραφείς: V. A. Parfyonov
Πηγή: Медицинский совет, Vol 0, Iss 18, Pp 20-26 (2014)
Θεματικοί όροι: профилактика болезни альцгеймера, лечение болезни альцгеймера, ингибиторы центральной ацетилхолинэстеразы, мемантина гидрохлорид, холина аль-фосцерат, исследование ascomalva, migraine, pain medications, triptans, acetylsalicylic acid, paracetamol, caffeine, excedrin, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/794; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/d0a8705275364c68b4bd5db2beb0770b
-
4Academic Journal
Συγγραφείς: A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya, А. А. Науменко, Д. О. Громова, Н. В. Трофимова, И. А. Преображенская
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 4 (2016); 91-97 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 4 (2016); 91-97 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-4
Θεματικοί όροι: когнитивно-моторный тренинг, cerebral amyloidosis, basic symptomatic treatment, central acetylcholinesterase inhibitors, NMDA receptor blockers, akatinol memantine, gantenerumab, nootropic therapy, cerebrolysin, non-drug exposures, cognitive-motor training, церебральный амилоидоз, базисное симптоматическое лечение, ингибиторы центральной ацетилхолинэстеразы, блокаторы NMDA-рецепторов, акатинол мемантин, гантенерумаб, нооторопная терапия, церебролизин, нелекарственные методы воздействия
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/680/619; Гаврилова СИ, Федорова ЯБ, Колыхалов ИВ и др. Терапевтический потенциал Церебролизина в превентивной терапии болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;(8): 24-9. [Gavrilova SI, Fedorova YaB, Kolykhalov IV, et al. The therapeutic potential of Cerebrolysin in the preventative treatment of Alzheimer's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(8):24-9. (In Russ.)].; Гусев ЕИ, Гехт АБ, Белоусов ЮБ и др. Клинические и фармакоэкономические особенности применения Церебролизина в восстановительном лечении ишемического инсульта. Журнал неврологии и психиатрии им. С.С.Корсакова. 2007;(10):26-33. [Gusev EI, Gekht AB, Belousov YuB i dr. Clinical and pharmacoeconomic peculiarities of application of Cerebrolysin in rehabilitation of ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;(10):26-33. (In Russ.)].; Захаров ВВ, Яхно НН. Нарушения памяти. Москва: ГЭОТАР-Медиа; 2001. 160 с. [Zakharov VV, Yakhno NN. Narusheniya pamyati [Memory impairments]. Moscow: GEOTAR-Media; 2001. 160 p.]; Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi:10.1517/14712598.2011.578573. Epub 2011 Apr 20.; Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Руководство для врачей. 3-е издание. Москва: МЕДпресс-информ; 2011. С. 53-75. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachei [Dementia. A guide for physicians]. 3rd edition. Moscow: MEDpress-inform; 2011. P. 53-75.]; Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007 Feb 13;68(7):501-8. Epub 2006 Oct 25.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 224 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 224 p.]; Преображенская ИС, Громова ДО. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский совет. 2014;(10):36-42. [Preobrazhenskaya IS, Gromova DO. Some aspects of the therapy of neurodegenerative dementia. Meditsinskii sovet. 2014;(10):36-42. (In Russ.)].; Brickman AM, Siedlecki KL, Stern Y. Cognitive and Brain reserve. In: Depp CA, Jeste DV, editors. Successful Cognitive and Emotional Aging. Arlington: American Psychiatric Publishing, Inc; 2010. P. 157-72.; Erickson KI, Colcombe SJ, Wadhwa R, et al. Training-induced plasticity in older adults: effects of training on hemispheric asymmetry. Neurobiol Aging. 2007 Feb;28(2):272-83. Epub 2006 Feb 9.; Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol. 2001 Apr;49(4):433-42.; Dickerson BC, Goncharova I, SullivanMP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001 Sep-Oct;22(5): 747-54.; Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRImeasures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002 Apr 23;58(8):1188-96.; Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluidregistered serial MRI. Proc Natl Acad Sci USA. 2002 Apr 2;99(7):4703-7.; Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-59.; Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006213. doi:10.1101/cshperspect.a006213.; Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28. doi:10.1016/S1474-4422(09)70299-6.; Whitwell JL. Longitudinal imaging: change and causality. Curr Opin Neurol. 2008 Aug;21(4):410-6. doi:10.1097/WCO.0b013e32830719d4.; Toyn JH, Rowley A, Matsuoka Y, et al. γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? Int JAlzheimers Dis. 2013;2013:849128. doi:10.1155/2013/849128. Epub 2013 Apr 18.; Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi:10.1517/14712598.2010.493872.; Novakovic D, Feligioni M, Scaccianoce S, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi:10.2147/DDDT.S53401.eCollection 2013.; Vellas B, Carrillo MC, Sampaio C, et al; EU/US/CTAD Task Force Members. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul;9(4):438-44. doi:10.1016/j.jalz.2013.03.007.; Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008 Dec 24;28(52):14156-64. doi:10.1523/JNEUROSCI.4147-08.2008.; Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 Feb;69(2):198-207. doi:10.1001/archneurol.2011.1538.Epub2011 Oct 10.; Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002 May;1(1):3.; Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004 Oct;10(10):1055-63.; Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008 Mar 4;148(5):370-8.; Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007 Jul 24;69(4 Suppl 1):S4-9.; Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006 Jan;13(1):43-54.; Rockenstein E, Adame A, Mante M, et al. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm (Vienna). 2005 Feb;112(2):269-82. Epub 2004 Jul 7.; Rockenstein E, Torrance M, Mante M, et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006 May 15;83(7): 1252-61.; Gauthier S, ProaЦo JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi:10.1159/000377672. Epub 2015 Mar 26.; Wey ZH, He QB, Wang H, et al. Metaanalysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm (Vienna). 2007;114(5):629-34. Epub 2007 Feb 23.; Weiner MW. Commentary on «Diagnosis of Alzheimer's disease: two decades of progress.» Central role of technology in the treatment and prevention of Alzheimer's disease. Alzheimers Dement. 2005 Oct;1(2):112-3.; Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults a meta-analytic study. Psychol Sci. 2003 Mar; 14(2):125-30.; Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013 Nov;21(11):1086-97. doi:10.1016/j.jagp.2013.02.018. Epub 2013 Jul 3.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct;43-44: 38-53. doi:10.1016/j.mam.2015.06.003.Epub 2015 Jun 10.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. 4th ed. JohnWiley & Sons; 2007. P. 356-60.; Yates LA, Orrell M, Spector A, Orgeta V. Service users' involvement in the development of individual Cognitive Stimulation Therapy (iCST) for dementia: a qualitative study. BMC Geriatr. 2015 Feb 6;15:4. doi:10.1186/s12877-015-0004-5.; Boripuntakul S, Kothan S, Methapatara P, et al. Short-Term Effects of Cognitive Training Program for Individuals with Amnestic Mild Cognitive Impairment: a Pilot Study. 2nd ed. Taylor & Francis; 2012. P. 138-49.; van Paasschen J, Clare L, Yuen KS, et al. Cognitive rehabilitation changesmemory-related brain activity in people with Alzheimer disease. Neurorehabil Neural Repair. 2013 Jun;27(5):448-59. doi:10.1177/1545968312471902. Epub 2013 Jan 31.; Belleville S, Bherer L. Biomarkers of cognitive training effects in aging. Curr Transl Geriatr Exp Gerontol Rep. 2012 Apr 19;1(2): 104-110. Print 2012 Jun.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/archneurol.2009.307.; Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesticmild cognitive impairment: a randomized controlled trial. BMC Neurol. 2012 Oct 31;12:128. doi:10.1186/1471-2377-12-128.; Schmidt W1, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013;35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.
-
5Academic Journal
Συγγραφείς: A. A. Naumenko, N. V. Vakhnina, А. А. Науменко, Н. В. Вахнина
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 2 (2016); 100-106 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 2 (2016); 100-106 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-2
Θεματικοί όροι: акатинол мемантин, vascular cognitive impairments, poststroke cognitive impairments, vascular dementia, glutamatergic system, central acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, akatinol memantine, сосудистые когнитивные нарушения, постинсультные когнитивные нарушения, сосудистая деменция, глутаматергическая система, ингибиторы центральной ацетилхолинэстеразы, антагонисты NMDA-рецепторов
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/616/566; Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 298 c. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 298 p.]; Захаров ВВ, Вахнина НВ, Громова ДО, Тараповская АА. Диагностика и лечение когнитивных нарушений после инсульта. Медицинский совет. 2015;(10):14-21. [Zakharov VV, Vakhnina NV, Gromova DO, Tarapovskaya AA. Diagnosis and treatment of cognitive impairment after stroke. Meditsinskii sovet. 2015;(10):14-21. (In Russ.)].; Rasquin SM, Verhey FR, van Oostenbrugge RJ, et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1562-7.; Ihle-Hansen H, Thommessen B, Wyller TB, et al. Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment. Dement Geriatr Cogn Disord. 2011;32(6):401-7. doi:10.1159/000335361. Epub 2012 Feb 3.; Srikanth VK, Anderson JF, Donnan GA, et al. Progressive dementia after first-ever stroke: a community-based follow-up study. Neurology. 2004 Sep 14;63(5):785-92.; Srikanth VK, Thrift AG, Saling MM, et al. Increased risk of cognitive impairment 3 months after mild to moderate first-ever stroke: a Community-Based Prospective Study of Nonaphasic English-Speaking Survivors. Stroke. 2003 May;34(5):1136-43. Epub 2003 Apr 17.; Sachdev PS, Brodaty H, Valenzuela MJ, et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord. 2006;21(5-6):275-83. Epub 2006 Feb 10.; Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke. 2004 Jun;35(6):1264-8. Epub 2004 Apr 29.; Lisabeth LD, Sanchez BN, Baek J, et al. Neurological, functional, and cognitive stroke outcomes in Mexican Americans. Stroke. 2014 Apr;45(4):1096-101. doi:10.1161/ STROKEАHA.113.003912. Epub 2014 Mar 13.; Захаров ВВ, Вахнина НВ. Инсульт и когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2011;3(2):8-16. [Zakharov VV, Vakhnina NV. Stroke and cognitive disorders. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(2):8-16. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711- 2011-141; Вахнина НВ. Профилактика и лечение постинсультных когнитивных нарушений. Эффективная фармакотерапия. 2014;42(4): 32-9. [Vakhnina NV. Prevention and treatment of post-stroke cognitive impairment. Effektivnaya farmakoterapiya. 2014;42(4):32-9. (In Russ.)].; Захаров ВВ, Вахнина НВ. Особенности ведения пациентов с постинсультными ког- нитивными нарушениями. Атмосфера. Нервные болезни. 2011;(3):14-20. [Zakharov VV, Vakhnina NV. Management of patients with post-stroke cognitive impairment. Atmosfera. Nervnye bolezni. 2011;(3):14-20. (In Russ.)].; Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009 Nov;8(11):1006-18. doi:10.1016/S1474- 4422(09)70236-4. Epub 2009 Sep 24.; Tham W, Auchus AP, Thong M, et al. Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci. 2002 Nov 15;203-204:49-52.; Преображенская ИС, Науменко АА. Патогенез, диагностика и терапия болезни Альцгеймера. Медицинский совет. Неврология. 2015;(5):46-54. [Preobrazhenskaya IS, Naumenko AA. Pathogenesis, diagnosis and therapy of Alzheimer's disease. Meditsinskii sovet. Nevrologiya. 2015;(5):46-54. (In Russ.)].; Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции, руководство для врачей. Москва: МЕДпресс-информ; 2011. С. 53-75. [YakhnoNN, Zakharov VV, Lokshina AB, et al. Dementsii, rukovodstvo dlya vrachei [Dementia, a guide for physicians]. Moscow: MEDpressinform; 2011. P. 53-75.]; Chandra V, Ganguli M, Pandav R, et al. Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology. 1998 Oct;51(4):1000-8.; Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities. Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001 Feb 14; 285(6):739-47.; Чердак МА, Яхно НН. Постинсультные когнитивные расстройства. Журнал неврологiї iм. Б.М. Маньковського. 2013;(1):31-7. [Cherdak MA, Yakhno NN. Post-stroke cognitive disorders. Zhurnal nevrologії іm. B.M. Man'kovs'kogo. 2013;(1):31-7. (In Russ.)].; Мхитарян ЭА, Преображенская ИС. Бо- лезнь Альцгеймера и цереброваскулярные расстройства. Неврологический журнал. 2006;11(1):31-6. [Mkhitaryan EA, Preobrazhenskaya IS. Alzheimer's disease and cerebrovascular disorders. Nevrologicheskii zhurnal. 2006;11(1):31-6. (In Russ.)].; Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):321-30.; Patterson C, Feightner JW, Garcia A, et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008 Feb 26;178(5): 548-56. doi:10.1503/cmaj.070796.; Парфенов ВА, Захаров ВВ, Преображен- ская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. С. 1-106. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2014. P. 1-106.]; Barba R, Castro MD, del Mar Morin M, et al. Prestroke dementia. Cerebrovasc Dis. 2001;11(3):216-24.; Преображенская ИС. Постинсультные когнитивные расстройства: причины, клинические проявления, лечение. Фарматека. 2013;(9):49-53. [Preobrazhenskaya IS. Postinsul'tnye kognitivnye rasstroistva: prichiny, klinicheskie proyavleniya, lechenie. Farmateka. 2013;(9):49-53. (In Russ.)].; Чердак МА, Парфенов ВА. Когнитивные расстройства у пациентов, перенесших ишемический инсульт: обзор. Неврологический журнал. 2011;16(6):37-44. [Cherdak MA, Parfenov VA. Cognitive dysfunction in patients with ischemic stroke: a review. Nevrologicheskii zhurnal. 2011;16(6):37-44. (In Russ.)].; Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12.; Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004 Jan;128(1):32-8.; Hulette CM. Brain banking in the United States. J Neuropathol Exp Neurol. 2003 Jul;62(7):715-22.; Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003 Apr;60(4):569-75.; Левин ОС. Когнитивные нарушения в практике невролога. Москва: МедПресс- информ; 2006. [Levin OS. Kognitivnye narusheniya v praktike nevrologa [Cognitive impairments in the practice of neurologist]. Moscow: MedPress-inform; 2006.]; Парфенов ВА. Артериальная гипертония и инсульт. Неврологический журнал. 2001;(6):4–7. [Parfenov VA. Hypertension and stroke. Nevrologicheskii zhurnal. 2001;(6):4–7. (In Russ.)].; Li X, Li D, Li Q, et al. Hippocampal subfeld volumetry in patients with subcortical vascular mild cognitive impairment. Sci Rep. 2016 Feb 15;6:20873. doi:10.1038/srep20873.; Kim GH, Lee JH, Seo SW, et al. Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiol Aging. 2015 Jan;36(1):485-91. doi:10.1016/j.neurobiolaging.2014.08.009. Epub 2014 Sep 28.; Захаров ВВ. Когнитивные нарушения после инсульта: медико-социальная значимость и подходы к терапии. Нервные болезни. 2015;(2):2-8. [Zakharov VV. Cognitive impairment after stroke: medical and social significance and approaches to therapy. Nervnye bolezni. 2015;(2):2-8. (In Russ.)].; Wu Y, Wang M, Ren M, et al. The effects of educational background on Montreal Cognitive Assessment screening for vascular cognitive impairment, no dementia, caused by ischemic stroke. J Clin Neurosci. 2013 Oct;20(10):1406- 10. doi:10.1016/j.jocn.2012.11.019. Epub 2013 Jul 24.; Brickman AM, Siedlecki KL, Stern Y. Cognitive and Brain reserve. In: Depp CA, Jeste DV, editors. Successful Cognitive and Emotional Aging. Arlington, USA: American Psychiatric Publishing, Inc; 2010. P. 157-172.; Яхно НН, Лавров АЮ. Изменения центральной нервной системы при старении. В кн.: Завалишин ИА, Яхно НН, Гаврилова СИ, редакторы. Нейродегенеративные болезни и старение (Руководство для врачей). Москва; 2001. С. 242 – 61. [Yakhno NN, Lavrov AYu. Changes of the Central nervous system during aging. In: Zavalishin IA, Yakhno NN, Gavrilova SI, editors. Neirodegenerativnye bolezni i starenie (Rukovodstvo dlya vrachei) [Neurodegenerative diseases and aging (Manual for doctors)]. Moscow; 2001. P. 242 – 61.]; Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA. 1997 Mar 12;277(10):813-7.; Singh-Manoux A, Marmot MG, Glymour M, et al. Does cognitive reserve shape cognitive decline? Ann Neurol. 2011 Aug;70(2):296-304. doi:10.1002/ana.22391. Epub 2011 May 11.; Zahodne LB, Glymour MM, Sparks C, et al. Education does not slow cognitive decline with aging: 12-year evidence from the victoria longitudinal study. J Int Neuropsychol Soc. 2011 Nov;17(6):1039-46. doi:10.1017/S13556177 11001044. Epub 2011 Sep 19.; Jorm A. The informant questionnare on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr. 2004 Sep;16(3):275-93.; Henon H, Durieu I, Lebert F, et al. Influence of pre-stroke dementia on early and delayed mortality in stroke patients. J Neurol. 2003 Jan;250(1):10-6.; Вахнина НВ, Никитина ЛЮ, Парфeнов ВА. Постинсультные когнитивные нарушения. Журнал неврологии и психиатрии им. С.С. Корсакова. Прил. Инсульт. 2008;(22):16-21. [Vakhnina NV, Nikitina LYu, Parfenov VA. Post-stroke cognitive impairment. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. Suppl. Stroke. 2008;(22):16-21. (In Russ.)].; Парфeнов ВА, Вахнина НВ, Никитина ЛЮ. Когнитивные нарушения после инсульта и их лечение мемантином. Клиническая геронтология. 2005;11(8):49-52. [Parfenov VA, Vakhnina NV, Nikitina LYu. Cognitive impairment after stroke and their treatment with memantine. Klinicheskaya gerontologiya. 2005;11(8):49-52. (In Russ.)].; Климов ЛВ, Парфeнов ВА. Когнитивные нарушения в остром периоде ишемического инсульта. Неврологический журнал. 2006;(11 Прил. 1):53-6. [Klimov LV, Parfenov VA Cognitive impairment in acute period of ischemic stroke. Nevrologicheskii zhurnal. 2006;(11 Suppl. 1):53-6. (In Russ.)].; Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of яuidregistered serial MRI. Proc Natl Acad Sci USA. 2002 Apr 2;99(7):4703-7.; Lehericy S, BaulacM, Chiras J, et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. AJNR Am J Neuroradiol. 1994 May;15(5):929-37. 49. Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol. 2001 Apr;49(4):433-42.; Dickerson BC, Goncharova I, SullivanMP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001 Sep-Oct; 22(5):747-54.; Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRImeasures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002 Apr 23;58(8):1188-96.; Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59.; Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Apr;2(4): a006213. doi:10.1101/cshperspect.a006213.; Whitwell JL. Longitudinal imaging: change and causality. Curr Opin Neurol. 2008 Aug;21(4): 410-6. doi:10.1097/WCO.0b013e32830719d4.; Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиат- рия, психосоматика. 2011;3(3):8-13. [Parfenov VA. Prevention of Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711- 2011-159; Morris MC, Evans DA, Tangney CC, et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006 Oct 24;67(8):1370-6.; Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Brain Res Bull. 2006 Mar 15;69(1):1-19. Epub 2005 Nov 21.; Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011 Jun;68(6):743-52. doi:10.1001/archneurol.2011.125.; Парфенов ВА, Науменко АА, Преобра- женская ИС. Лекарственные и нелекарственные методы лечения болезни Альцгеймера. Фарматека. 2015;(7):72-9. [Parfenov VA, Naumenko AA, Preobrazhenskaya IS. Lekarstvennye i nelekarstvennye metody lecheniya bolezni Al'tsgeimera. Farmateka. 2015;(7):72-9. (In Russ.)].; Вахнина НВ, Захаров ВВ. Опыт применения ривастигмина (экселона) в лечении постинсультных когнитивных нарушений. Неврологический журнал. 2009;14(4):42-6. [Vakhnina NV, Zakharov VV. Experience of use of rivastigmine (Exelon) in the treatment of post-stroke cognitive impairment. Nevrologicheskii zhurnal. 2009;14(4):42-6. (In Russ.)].; Преображенская ИС, Громова ДО. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский совет. 2014;(10):36-42. [Preobrazhenskaya IS, Gromova DO. Some aspects of the therapy of neurodegenerative dementia. Meditsinskii sovet. 2014;(10):36-42. (In Russ.)].; Baskys A, Hou AC. Vascular dementia: pharmacological treatment and perspectives. Clin Interv Aging. 2007;2(3):327-35.; Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007 Jul 24;69 (4 Suppl 1):S4-9.; Дамулин ИВ, Кононенко ЕВ. Статолокомоторные нарушения у больных с полушарным инсультом. Клиническая геронтология. 2007;13(8):42-9. [Damulin IV, Kononenko EV. Statolocomotor disorders in patients with hemispheric stroke. Klinicheskaya gerontologiya. 2007;13(8):42-9. (In Russ.)].; Ярыгин КН, Ярыгин ВН. Нейрогенез в центральной нервной системе и перспекти- вы регенеративной неврологии. Журнал неврологии и психиатрии им. С. С. Корсако- ва. 2012;112(1): 4-13. [Yarygin KN, Yarygin VN. Neurogenesis in the Central nervous system and prospects of regenerative neurology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(1): 4-13. (In Russ.)].; Захаров ВВ. Глутаматергическая терапия в восстановительном периоде после ишемического инсульта. Эффективная фармакотерапия. Неврология. 2014;(4):6-14. [Zakharov VV. Glutamatergic therapy in the rehabilitative period after ischemic stroke. Effektivnaya farmakoterapiya. Nevrologiya. 2014;(4):6-14. (In Russ.)].; Гаврилова СИ. Фармакотерапия болезни Альцгеймера. Москва: Пульс; 2003. 320 c. [Gavrilova SI. Farmakoterapiya bolezni Al'tsgeimera [Pharmacotherapy of Alzheimer's disease]. Moscow: Pul's; 2003. 320 p.]; Дамулин ИВ. Болезнь Альцгеймера и сосудистая деменция. Москва; 2002. 85 с. [Damulin IV. Bolezn' Al'tsgeimera i sosudistaya dementsiya [Alzheimer's disease and vascular dementia].Moscow; 2002. 85 p.]; Гусев ЕИ, Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2001. 325 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2001. 325 p.]; Areosa SA, Sheriff F, McShane R. Memantine for dementia. The Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003154.; Petrilli S, Durufle A, Nicolas B, et al. Prognostic factors in recovery of the ability to walk after stroke. J Stroke Cerebrovasc Dis. 2002 Nov-Dec;11(6):330-5.; Kleiser B, Diepers M, Geiger S, et al. Combned therapy with flunarizine and memantine of experimental intracerebral hematoma in rats. Neurol Psych. 1995;(3):219-224.; Яхно НН, Преображенская ИС, Захаров ВВ, Мхитарян ЭА. Эффективность мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал. 2010;15(2): 52-8. [Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. The efficacy of memantine in patients with non-demental cognitive disorders. Results of a multicenter clinical observations. Nevrologicheskii zhurnal. 2010;15(2):52-8. (In Russ.)].; Левин ОС, Юнищенко НА, Дударова МА. Эффективность акатинола мемантина при умеренно выраженном когнитивном расстройстве. Журнал неврологии и психиатрии им С.С. Корсакова. 2009;(7):36-42. [Levin OS, Yunishchenko NA, Dudarova MA. The effectiveness of akatinol memantine in patients with moderate cognitive disorder. Zhurnal nevrologii i psikhiatrii im S.S. Korsakova. 2009;(7):36-42. (In Russ.)].
-
6Academic Journal
Συγγραφείς: Svetlana Viktorovna Verbitskaya
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 5, No 2S (2013): Special issue "Stroke"; 46-49 ; Неврология, нейропсихиатрия, психосоматика; Vol 5, No 2S (2013): Special issue "Stroke"; 46-49 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2013-2S
Θεματικοί όροι: ингибиторы центральной ацетилхолинэстеразы, post-stroke dementia, akatinol memantine, central acetylcholinesterase inhibitors, постинсультная деменция, акатинол мемантин
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/209/212; Вахнина НВ, Никитина ЛЮ, Парфенов ВА, Яхно НН. Постинсультные когнитивные нарушения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(S22):16–21. [Vakhnina NV, Nikitina LYu, Parfyonov VA, Yakhno NN. Post-stroke cognitive disturbances. Neuroscience and Behavioral Physiology. 2008;108(S22):16–21.] Дамулин ИВ, Парфенов ВА, Скоромец АА, Яхно НН. Нарушения кровообращения в головном и спинном мозге. В кн.: Болезни нервной системы. Руководство для врачей. Т. 1. Под ред. НН Яхно. Москва: Медицина; 2005. С. 232–303. [Damulin IV, Parfenov VA, Skoromets AA, Yakhno NN. Narusheniya krovoobrashcheniya v golovnom i spinnom mozge. V kn.: Bolezni nervnoy sistemy. Rukovodstvo dlya vrachey. T. 1. Pod red. NN Yakhno. Moscow: Meditsina; 2005. P. 232–303.] Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskiy insul't. Moskva: MIA; 2012. 288 p.] Яхно НН. Когнитивные расстройства в неврологической практике. Неврологический журнал. 2006;11(S1):4–12. [Yakhno NN. Cognitive impairment in neurological clinical practice. Nevrologicheskiy zhurnal. 2006;11(S1):4–12.] O’Brien J, Ames D, Gustafson L еt al., editors. Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Martin Dunitz; 2004. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672–713. DOI:10.1161/STR.0b013e3182299496. Epub 2011 Jul 21. Henon H, Pasquie F, Leys D. Poststroke Dementia. Cerebrovasc Dis. 2006;22(1):61–70. DOI:10.1212%2FWNL.57.7.1216. Epub 2006 Apr 26. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507. DOI:10.1159/000131083. Epub 2008 May 6. Вербицкая СВ, Парфенов ВА. Клинический опыт применения меманитина при постинсультной деменции. Неврологический журнал. 2008;13(4):45–7. [Verbitskaya SV, Parfenov VA. Clinical experience of memantine administration in patients with post-stroke dementia. Nevrologicheskiy zhurnal. 2008;13(4):45–7.] Black S, Roma’n GC, Geldmacher DS et al.; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323–30. DOI:10.1161%2F01.STR.0000091396.95360.E1. Epub 2003 Sep 11. Roma’n GC, Salloway S, Black SE et al. Randomized, placebo controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 2010;41(6):1213–21. DOI:10.1161/STROKEAHA.109.570077. Epub 2010 Apr 15. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;359(9314):1283–90. Auchus AP, Brashear HR, Salloway S et al.; GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69(5):448–58. DOI:10.1212%2F01.wnl.0000266625.31615.f6. Narasimhalu K, Effendy S, Sim CH et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand. 2010;121(4):217–24. DOI:10.1111/j.1600-0404.2009.01263.x. Epub 2009 Sep 26. Orgogozo JM, Rigaud AS, Sto¨ffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–39. DOI:10.1161%2F01.STR.0000020094.08790.49. Wilcock G, Mobius HJ, Stoffler A; MMM 500 Group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297–305. DOI:10.1097%2F00004850-200211000-00005. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782–92. DOI:10.1016%2FS1474-4422%2807%2970195-3. Вербицкая СВ, Парфенов ВА. Вторичная профилактика инсульта в амбулаторных условиях. Неврологический журнал. 2011;16(1):42–46. [Verbitskaya SV, Parfenov VA. The secondary prevention of stroke in out-patient conditions. Nevrologicheskiy zhurnal. 2011;16(1):42–46.]